NDY was engaged by CSL Seqirus in September 2021 as the principal design consultant for Project Banksia, their new advanced-manufacturing biopharmaceutical facility in Melbourne, Australia.

Once complete Project Banksia will deliver a state-of-the-art facility that will use innovative cell-based technology to produce influenza vaccines for use in both influenza pandemics and seasonal vaccination programs. The new facility will also produce unique products important to Australia’s public health needs – including antivenom for Australian snakes, spiders and marine creatures, and the world’s only human vaccine for Q-Fever.

Our team is engaged for design services for all building services, architecture, structure and specialist disciplines, with the support and collaboration of NDY and CSL Seqirus’ design partners. The breadth of specialist design skills our project team carries is essential to deliver such a complex facility.

Having obtained formal stage gate approvals for Concept Design & Basic Design, our team has completed Detailed Design, and is finalising a ‘zero clash’ construction model coordinated with procured manufacturing process equipment. In parallel, due to the complex nature of delivering this type of project, our team is providing technical assistance to the BESIX Watpac led construction team. The collaboration between Client | Design | Construction has been a highlight of this journey from the beginning.

A project of both national and global public health significance, the new facility will be an important addition to the global influenza manufacturing supply chain and our team at NDY could not be any prouder to be a project delivery partner.

JOIN US ON SOCIAL MEDIA
SUBSCRIBE TO OUR NEWSLETTER